🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Birmingham
Clinical trial register · United Kingdom · industry-sponsored

Clinical Trials in Birmingham

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a UK site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full UK registry across all sponsors is far larger. UK studies may also be registered separately on ISRCTN.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 2846 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 20 Sep 2026, 03:15 UTC
2846
Studies in scope
industry-sponsored, all four open statuses
1377
Recruiting now
open to new participants
539
Lead sponsors
across recruiting studies
Top sites
London 2003 Manchester 674 Birmingham 469 Glasgow 437 Cambridge 416
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca31 Janssen Research & Development, LLC17 Merck Sharp & Dohme LLC16 Eli Lilly and Company14 Bristol-Myers Squibb14
Site city
London2003 Manchester674 Birmingham469 Glasgow437 Cambridge416
All 426 cities
Target enrolment
to
469 of 2846 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
UK sites
Start
Active, closed
A Study of Brepocitinib in Adults With Active, Non-Infectious, Non-Anterior Uveitis
NCT06431373Uveitis, Posterior, Uveitis, Intermediate, Uveitis
Priovant Therapeutics, Inc.
Phase 3
371
London, Maidstone, Middlesbrough, Oxford, Sheffield, Birmingham, Bradford, Bristol
2024-09-11
Recruiting
A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease
NCT06572384Lung Diseases, Interstitial
GlaxoSmithKline
Phase 3
440
Leicester, Birmingham, London
2024-09-11
Recruiting
A Study to Investigate the Safety and Effectiveness of a Coagulation Factor IX Gene Insertion Therapy (REGV131-LNP1265) in Pediatric, Adolescent and Adult Participants With Hemophilia B
NCT06379789Hemophilia B
Regeneron Pharmaceuticals
Phase 1/2
130
Glasgow, Birmingham, Cambridge, London
2024-09-11
Recruiting
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
NCT06528314NASH - Nonalcoholic Steatohepatitis, MASH - Metabolic Dysfunction-Associated Steatohepatitis
Akero Therapeutics, Inc
Phase 3
2,150
London, Nottingham, Birmingham, Newcastle upon Tyne, Whitechapel
2024-09-04
Active, closed
Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN)
NCT06564142Immunoglobulin A Nephropathy
Alpine Immune Sciences Inc, A Subsidiary of Vertex
Phase 3
605
Belfast, Birmingham, Bristol, Cambridge, Glasgow, Gloucester, Leicester, London
2024-08-30
Recruiting
EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)
NCT06531824Kidney Disease, Chronic
Boehringer Ingelheim
Phase 3
11,000
Antrim, Basildon, Belfast, Birmingham, Blackburn, Brighton, Bristol, Bury St Edmunds
2024-08-30
Active, closed
Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)
NCT06486441Endometrial Cancer
Gilead Sciences
Phase 3
640
Birmingham, Cambridge, Leeds, Leicester, London, Northwood
2024-08-28
Recruiting
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
NCT06395103B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma, Burkitt Lymphoma, Neuroblastoma
Merck Sharp & Dohme LLC
Phase 1/2
90
Birmingham, Newcastle upon Tyne, London, Sutton, Cardiff
2024-08-16
Recruiting
Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer
NCT06467357Biliary Tract Cancer
AstraZeneca
Phase 3
620
Birmingham, Dundee, Glasgow, Greater London, Leeds, London
2024-08-12
Active, closed
Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy
NCT06449209Extensive-stage Small-cell Lung Cancer, Small-cell Lung Cancer
BioNTech SE
Phase 2
110
Birmingham, Cardiff, Dundee, Exeter, Huddersfield, Leeds, London, Newcastle upon Tyne
2024-08-05
Active, closed
An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 60 Years of Age and Above Who Participated in RSV OA=ADJ-006 Study
NCT06534892Respiratory Syncytial Virus Infections
GlaxoSmithKline
Phase 3
10,212
Bebington, Belfast, Birmingham, Bradford on Avon Wiltsh, Cardiff, Corby, Eynsham, Glasgow
2024-08-01
Active, closed
A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Women With Breast Cancer Who Are Having Hormone Therapy
NCT06440967Hot Flashes
Astellas Pharma Global Development, Inc.
Phase 3
982
Bebington, Guildford, Aberdeen, Birmingham, Bristol, Cambridge, Glasgow, Liverpool
2024-07-31
Recruiting
Vitaccess Real MG Registry
NCT06064461Myasthenia Gravis
Vitaccess Ltd
Observational
600
London, Birmingham
2024-07-31
Active, closed
A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG.
NCT06517758Generalized Myasthenia Gravis
Novartis Pharmaceuticals
Phase 3
146
Inverness, Swinton, Birmingham, London, Southampton
2024-07-31
Active, closed
A Study of JNJ-64042056 in Participants With Preclinical Alzheimer's Disease
NCT06544616Alzheimer Disease
Janssen Pharmaceutica N.V., Belgium
Phase 2
55
Bath, Birmingham, Bristol, Edinburgh, Guildford, London, Oxford, Plymouth
2024-07-22
Active, closed
A Phase 1b/2a, Open-label Single Ascending Doses and Multiple Ascending Doses Study in Participants With Pi*ZZ AATD
NCT06405633Alpha-1 Antitrypsin Deficiency
Wave Life Sciences USA, Inc.
Phase 1/2
24
Birmingham, Cambridge, London
2024-07-19
Recruiting
Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation
NCT06252649Metastatic Colorectal Cancer
Amgen
Phase 3
450
Birmingham, Glasgow, London, Maidstone, Northwood, Sheffield, Sutton
2024-07-17
Recruiting
Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis
NCT06465810Transthyretin Amyloidosis, ATTR-CM, ATTRv-PN, ATTR
AstraZeneca
Observational
1,850
Birmingham, Glasgow, London
2024-06-25
Recruiting
A Trial of Lu AG13909 in Adult Participants With Cushing's Disease
NCT06471829Cushing's Disease
H. Lundbeck A/S
Phase 2
18
Manchester, Birmingham
2024-06-19
Recruiting
IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)
NCT06112314Advanced Melanoma
Immunocore Ltd
Phase 3
680
Birmingham, Cambridge, Glasgow, Liverpool, London, Manchester, Oxford, Surrey Quays
2024-06-05
Recruiting
Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
NCT06479135Myelofibrosis, Post-PV MF, Post-ET Myelofibrosis, Primary Myelofibrosis
Kartos Therapeutics, Inc.
Phase 3
600
Birmingham, Boston, Cambridge, Cardiff, Edinburgh, Gloucester, Harrogate, Leicester
2024-06-03
Active, closed
A Study Evaluating Anvumetostat in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103)
NCT06360354Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers
Amgen
Phase 1
120
Birmingham, London
2024-05-29
Recruiting
Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)
NCT06353386Prostatic Neoplasms, Castration-Resistant
Merck Sharp & Dohme LLC
Phase 1/2
220
Cambridge, Glasgow, Preston, London, Birmingham
2024-05-20
Active, closed
Phase 3 Study of ALXN1850 in Treatment-Naïve Pediatric Participants With HPP
NCT06079359Hypophosphatasia
Alexion Pharmaceuticals, Inc.
Phase 3
30
Birmingham
2024-05-14
Recruiting
A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast
NCT06238622Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis
Boehringer Ingelheim
Phase 3
1,700
Aberdeen, Birmingham, Bristol, Edinburgh, Exeter, Lancaster, Leeds, London
2024-05-06
Rows per page Showing 176–200 of 469
Previous 6 7 8 9 10 Next
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a UK investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 20 September 2026. https://priyalifescience.com/clinical-trials-uk/city/birmingham

Query this register directly
GET /api/trials?country=uk&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the UK Pharma Salary Guide, or see the Ireland, EU and USA registers.